He was prescribed liraglutide (0.6mg daily for one week, then 1.2mg daily for five weeks) given concomitant challenges with glucose control
First, and most obviously, GLP-1 may emerge as a promising candidate biomarker for the early detection of gut injury in humans, while also representing a novel therapeutic target for the control of inflammation in the gut
In a randomized, controlled clinical study (Study G), adult patients with type 2 diabetes were randomized to 5 years of treatment with once-daily insulin glargine or twice-daily NPH insulin
L., Sitruk-Ware, R., Long, J., Bai, F., Hull, L., Bremner, W
Similar to our previous RNA-seq analysis, we demonstrate that treatment with GLP-1MK-801 significantly regulates around 150 times the number of hypothalamic transcripts relative to the weight-matched semaglutide-treated group, emphasizing a mode of action for GLP-1MK-801 that involves biological pathways independent of the GLP-1 receptor signalling pathway (Fig